Kevin Bunker, Ph.D.

Kevin Bunker, Ph.D.

Former Chief Scientific OfficeratZentalis Pharmaceuticals· In proxies 2021–2023

Pay in FY2022+104% from the year before · Zentalis Pharmaceuticals stock -76.0% the same year

Kevin Bunker, Ph.D. was paid $5.7M in FY2022 (Dec), up 104%. Zentalis Pharmaceuticals stock fell 76.0% that year.

Pay$100 in the stock at the end of FY20 → $39
Pay is from the Summary Compensation Table of each Zentalis Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Zentalis PharmaceuticalsPublic company · 5 yr
    • Former Chief Scientific Officer2021 – Present · 5 yrStock in role -96%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?